The Growing Impact Of Oncotarget In The Medical World

Oncotarget is a free journal that has made a name for itself in the medical world. It was founded in 2010 and has significantly grown in terms of its impact. It is published by Impact Journals. The journal was measured by Thomson Reuters JCR to find out its impact factor. In 2011 Oncotarget was at 4.784 while in the year 2016/2017 it was at 5.168. There have also been increased citations from the journal proving its success. It has also been given the highest ranking by Scopus because of the positive contributions made.The main reason Oncotarget was started was to touch on oncology and the research that is being done in this particular area. The information given goes in depth. The opinion of patients in regards to different treatment methods is captured. This information is important to individuals who might be in the same condition as the patient.

After a number of trials, if the new procedure is considered worthwhile, it will be taken up. There are often different treatment methods that are discovered each day and various medical personnel need to know about them.The Official Website for the journal makes the material they publish more accessible. More people are online these days and sparing sometime to find out about their health is made easy because of the site. Each article that is published depends on what people want to know in that particular period. The publications are done on a weekly basis meaning content has to be planned in good time.

The journal is reviewed by other medics ensuring that the content that is posted is legit. The website has a section for reviews whereby individuals can talk about their experience and read about what others have to say.Time after time the journal keeps growing. It has been able to link researchers and other stakeholders in the medical field. Oncotarget has widened its scope from not only focusing on oncology but also other areas such as neurology, cardiology and pharmacology. Articles such as endocrinology and metabolism are also included. Focusing on many disciplines will see the journal becoming even more successful in the near future.

Jim Tananbaum’s Success is a Product of His Persistence and Dedication

Jim Tananbaum heads Foresite Capital, a reputable firm he founded in 2011 that supplies capital, networks, and information to upcoming healthcare leaders. Jim has always been an enthusiast of combining science with computer science and healthcare, which has formed the basis of his career. His inspiration comes from the ways the combination can work in solving healthcare complex issues. He has had numerous mentors along his journey, and he is dedicated to working with others of like mind to drive change in the healthcare industry.

What Worked for Him

Over the 25 years of his career as an entrepreneur in healthcare and an investment strategist, Jim Tananbaum realized that starting out in healthcare industry requires huge capital and time. This realization led to the birth of Foresite where he offers entrepreneurs and companies the much-needed incentives. Jim spends most of his time brainstorming with his team members and other leaders in the healthcare industry, which allows him to bring his ideas to life. He believes in the power of teamwork where all members complement each other to bring about excellent performance and success. Jim loves adding knowledge, which helps him get the best healthcare solutions. He is also committed and persistent in carrying out his duties, which has seen his firm and innovation grow. These two traits have also played a key role in helping him overcome tough times. His advice to other entrepreneurs is to carry out due diligence before making any investment. He also advises on believing in oneself, noting that combining what one believes in with what other people think is best often leads to unnecessary compromises. He adds on the importance of growing businesses on what is ideal for growth in the entrepreneur’s perspective rather than the traditional ways.

About Jim Tananbaum

Jim Tananbaum previously co-founded several other companies, including GelTex Pharmaceuticals, Theravance Inc., Prospect Venture Partners, and Sierra Partners. He has also been involved in several other organizations, such as Amira Pharmaceuticals, Amerigroup, Healtheon, and Jazz Pharmaceuticals.

Jim Tananbaum enrolled for a science degree science at Yale University and decided to specialize in the fields of engineering, mathematics, and computer science. He got his medical doctor degree from the Harvard University. Later on, he completed his master’s thesis and graduated from the esteemed Massachusetts Institute of Technology. Check out his page